The identification of ketotifen as a novel cardioprotective agent in patients undergoing anthracyclines chemotherapy

Objective: The present study aimed to investigate the possible cardioprotective effects of ketotifen and to assess its activity as an iron-chelating agent in patients receiving anthracyclines for the treatment of breast cancer. Patients & Methods: This was a randomized, prospective, controlled clinical trial. One hundred eleven eligible patients with breast cancer (age range, 30-60 years) were scheduled to receive anthracyclines chemotherapy. The patients were divided into two groups: Patients (n = 56) assigned to the ketotifen group received ketotifen 1 mg three times daily for six consecutive cycles of treatment, and patients assigned to the control group (n = 55) without ketotifen treatment. The echocardiogram for each patient was recorded two times at baseline and the end of the study. As well, blood samples were collected from all patients. Results: The findings showed a statistically significant reduction in the mean serum levels of common cardiotoxicity accompanied biomarkers in the ketotifen group compared with the control group (P ≤ 0.05). The mean serum levels of total iron-binding capacity were significantly elevated in the ketotifen group (P ≤ 0.001). There was a direct correlation between the mean serum levels of iron and that of lactate dehydrogenase (LDH) (r = + 0.79). On the other hand, there were indirect correlations between mean serum levels of LDH and both the percentage of ejection fraction and the total iron-binding capacity (r = - 0.69 and -0.697, respectively). Conclusion: Oral administration of ketotifen appears to be efficient and safe as a novel cardioprotective agent for the prevention of anthracyclines induced cardiotoxicity. Additionally, ketotifen suggested a beneficial effect in iron overload inducing diseases such as COVID-19.

Download Full-text

Novel use of Ketotifen as a cardio-protective agent in patients undergoing anthracycline chemotherapy

10.22541/au.160992639.92887113/v1 ◽

2021 ◽

Author(s):

hosny elewa ◽

Naser elberay ◽

amany elsharif ◽

Walaa Keshk ◽

zeinab zalat

Keyword(s):

Breast Cancer ◽

Binding Capacity ◽

Serum Levels ◽

Total Iron ◽

Control Group ◽

Iron Binding ◽

Total Iron Binding Capacity ◽

The Mean ◽

Iron Binding Capacity ◽

Anthracycline Chemotherapy

Objective: The present study aimed to investigate the possible cardioprotective effects of ketotifen and to assess its activity as an iron-chelating agent in patients receiving anthracyclines for the treatment of breast cancer. Patients & Methods: This was a randomized, prospective, controlled clinical trial. 111 eligible patients with breast cancer (age range, 30-60 year) were scheduled to receive anthracycline chemotherapy. The patients divided into two groups: Patients (n=56) assigned to The ketotifen group received ketotifen 1 mg three times daily for six consecutive cycles of treatment, and patients assigned to The control group (n= 55) without ketotifen treatment. The echocardiogram for each patient was recorded two times at baseline and at the end of the study. As well, blood samples were collected from all patients. Results: The findings showed a statistically significant reduction in the mean serum levels of common cardiotoxicity accompanied biomarkers in The ketotifen group compared with The control group (P ≤ 0.05). The mean serum levels of total iron-binding capacity was significantly elevated in The ketotifen group (P ≤ 0.001). There was a direct correlation between the mean serum levels of iron and that of lactate dehydrogenase (LDH) (r = + 0.79). On the other hand, there were indirect correlations between mean serum levels of LDH and both the percentage of ejection fraction and the total iron-binding capacity (r = - 0.69 and -0.697, respectively). Conclusion: Oral administration of ketotifen appears to be efficient and safe as a novel cardioprotective agent for the prevention of anthracyclines induced cardiotoxicity. Additionally, ketotifen suggested a beneficial effect in iron overload inducing diseases such as COVID-19.

Download Full-text

Temporal Variation of Serum Levels of Vitamin B12 Folate, Iron and Total Iron-Binding Capacity

Gerontology ◽

10.1159/000212391 ◽

1980 ◽

Vol 26 (1) ◽

pp. 34-42 ◽

Cited By ~ 2

Author(s):

M.S. Pathy ◽

R.G. Newcombe

Keyword(s):

Vitamin B12 ◽

Temporal Variation ◽

Binding Capacity ◽

Serum Levels ◽

Total Iron ◽

Iron Binding ◽

Total Iron Binding Capacity ◽

Iron Binding Capacity

Download Full-text

EFEKTIFITAS EKSTRAK DAUN KELOR (Moringa oleifera lam) DALAM MEMPERBAIKI PROFIL SERUM IRON, SATURASI TRANSFERIN, DAN TOTAL IRON BINDING CAPACITY TIKUS PUTIH JANTAN DIET RENDAH ZAT BESI

Herb-Medicine Journal ◽

10.30595/hmj.v3i1.6365 ◽

2020 ◽

Vol 3 (1) ◽

pp. 1

Author(s):

Diah Hermayanti ◽

Fathiyah Syafitri

Keyword(s):

Serum Iron ◽

Moringa Oleifera ◽

Binding Capacity ◽

Negative Control Group ◽

Negative Control ◽

Total Iron ◽

Control Group ◽

Iron Binding ◽

Total Iron Binding Capacity ◽

Iron Binding Capacity

Background : Iron deficinecy can cause anemia which affect health and work productivity. Moringa oleifera leaves contain a lot of iron and vitamin C, are thought to increase serum iron levels, transferin saturation, and improve total iron binding capacity.Objectives : To determine the effectiveness of Moringa oleifera lam. leaf extract on serum iron levels, transferin saturation, and total iron binding capacity in white rats (Rattus novergicus strain wistar) given a diet low in iron (Fe).Materials and methods : true experimental research using post test only control group design. The object of theis study was thirty male white mice (Rattus novergicus strain wistar) who were given a low iron diet. The study was divided into negative control group, positive control, treatment groups with a dose of Moringa leaf extract 400 mg/kg BW, 800 mg/kgBW, 1,600 mg/kg/BW, an the ferro fumaras control group (FF) 175 mg/200 BW.Results and discussion : Multivariate manova serum iron 0.001 (p<0.05), TBC 0.19 (P>0.05), and transferin saturation 0.001(p<0.05). In the post Hoc Tukey the mean serum iron and transferin saturation appeared to differ significant in the negative control group with all the other treatment groups, but did not show a significant diffrence beetwen the positive control group, FF Group, and the treatment groups.Conclusion : The adminstration of Moringa oleifera leaf extractwas less significant in improving serum iron levels, transferin saturation, and total iron binding capacity of male white mice induced by a low iron diet.

Download Full-text

Serum levels of vitamin D, magnesium, calcium, iron, and total iron binding capacity in HIV-infected patients

HIV & AIDS Review ◽

10.5114/hivar.2019.83845 ◽

2019 ◽

Vol 18 (2) ◽

pp. 148-152

Author(s):

Alireza Janbakhsh ◽

Mandana Afsharian ◽

Mazaher Ramezani ◽

Hamid Reza Mozaffari ◽

Masoud Sadeghi

Keyword(s):

Vitamin D ◽

Binding Capacity ◽

Serum Levels ◽

Total Iron ◽

Iron Binding ◽

Total Iron Binding Capacity ◽

Calcium Iron ◽

Iron Binding Capacity

Download Full-text

Extra ordinary high blood lead levels in Mashhad,Iran: a one-year study in a referral center

Physiology and Pharmacology ◽

10.32598/ppj.25.2.40 ◽

2021 ◽

Vol 25 (2) ◽

pp. 116-124

Author(s):

Samaneh Boroumand-Noughabi ◽

◽

Mohammad Reza Keramati ◽

Zahra Sadrzadeh Sadrzadeh, ◽

Zohreh Asadi ◽

...

Keyword(s):

Binding Capacity ◽

Lead Toxicity ◽

Blood Lead ◽

Total Iron ◽

Iron Binding ◽

Total Iron Binding Capacity ◽

Cell Counts ◽

Blood Cell Counts ◽

The Mean ◽

Iron Binding Capacity

Introduction: Lead is a heavy metal with vast usage in the industry. Lead toxicity affects any organ in the body. It causes various clinical presentations, which leads to diagnostic complexity. Regarding recent increased observation of cases with lead toxicity in our center, we aimed to evaluate the frequencies of lead toxicity in patients referred to Imam-Reza Hospital’s laboratory and find a possible relationship between the blood lead level (BLL) and hematological and biochemical tests. Methods: From 2016 to 2017, the patients referred to Imam-Reza hospital’s laboratory to detect BLL enrolled in the study. Among them, 254 adult cases with BLLs≥10 μg/dl were selected. Complete blood counts and peripheral blood smear were done. Other lab data were extracted from hospital files. Results: The mean BLL of 1649 participants was 59.11±116.25 μg/dl, ranging from 0 to 1580. Sixty nine percent of them had lead toxicity. Eighty-one percent (n=1341) of patients were males and 18.7% (n=308) were females. In 254 selected cases, the mean BLL was 138.17±189.98 μg/dl. There were significant inverse correlations between BLL and red blood cell counts, hemoglobin, mean cell hemoglobin, total iron-binding capacity, target shape and basophilic stippling, as well as positive correlations between BLL and white blood cell counts, red cell distribution width, neutrophil counts and iron. Conclusion: Lead toxicity seems to be more frequent than it is expected. Patients with unexplained anemia with increased iron and decreased total iron-binding capacity are better to be evaluated for BLL.

Download Full-text